SCHEMBL1635228

SCHEMBL1635228

CCOC(=O)C1CC12CC(C)CC(C)C2

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
PPM1B O75688 1/20 0.37
PTPN1 P18031 1/20 0.37
PPP1CC P36873 1/20 0.37
LMNA P02545 3/20 0.35
MAPT P10636 2/20 0.35
ALDH1A1 P00352 3/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
KDM4E B2RXH2 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23599469 0.80 PPM1B (0.41) CYP3A4CYP2D6CYP2C9CYP2C19PPM1B
SCHEMBL30148892 0.79 PPM1B (0.44) CYP3A4CYP2D6CYP2C9CYP2C19PPM1B
SCHEMBL1634121 0.78 ALDH1A1 (0.46) CYP3A4CYP2D6CYP2C9CYP2C19PPM1B
SCHEMBL16369922 0.78 ALDH1A1 (0.43) CYP3A4CYP2D6CYP2C9CYP2C19PPM1B
SCHEMBL30148891 0.78 PPM1B (0.39) CYP3A4CYP2D6CYP2C9CYP2C19PPM1B
SCHEMBL1634763 0.76 ALDH1A1 (0.49) CYP3A4CYP2D6CYP2C9CYP2C19PPM1B
SCHEMBL1635627 0.76 ALDH1A1 (0.49) CYP3A4CYP2D6CYP2C9CYP2C19PPM1B
SCHEMBL1634765 0.76 ALDH1A1 (0.49) CYP3A4CYP2D6CYP2C9CYP2C19PPM1B
SCHEMBL14699452 0.76 CYP3A4 (0.38) CYP3A4CYP2D6CYP2C9CYP2C19PPM1B
SCHEMBL1634178 0.75 LMNA (0.37) CYP3A4CYP2D6CYP2C9CYP2C19PPM1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932245-B2 Spirocyclopropyl amides and acids and their therapeutic applications ABBOTT LABORATORIES (US) 2011-04-26 US disclosed
EP-1558230-B1 SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LAB (US) 2008-12-31 EP disclosed
EP-1558230-A1 SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS Abbott Laboratories (US) 2005-08-03 EP disclosed
US-20040204396-A1 Spirocyclopropyl amides and acids and their therapeutic applications ABBVIE INC. 2004-10-14 US disclosed
WO-2004037240-A1 SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LABORATORIES (US) 2004-05-06 WO disclosed
US-20040077616-A1 Spirocyclopropyl amides and acids and their therapeutic applications ABBOTT LABORATORIES 2004-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077616-A1 Spirocyclopropyl amides and acids and their therapeutic applications SCN1A, SCN1B, SCN10A CYP3A4 1668/4885CYP2D6 650/4885CYP2C9 770/4885
US-20040204396-A1 Spirocyclopropyl amides and acids and their therapeutic applications SCN1A, SCN1B, SCN10A CYP3A4 1668/4885CYP2D6 650/4885CYP2C9 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.